Abstract:Background: Cisplatin (DDP)-based chemotherapy is commonly adopted as the first-line treatment for patients with oesophageal squamous cell carcinoma (OSCC), but the high rate of drug resistance limits its clinical application and the underlying mechanisms at play remain unclear. The aims of this study were to elucidate the role of abnormal signal transmission and metabolism in the chemoresistance of OSCC under hypoxia and to identify targeted drugs that enhance the sensitivity of DDP chemotherapy. Methods: Upregulated genes in OSCC were determined by RNA sequencing (RNA-seq), the Cancer Genome Atlas (TCGA) database, immunohistochemistry (IHC), real-time quantitative PCR (RT-qPCR), and western blotting (WB). The clinicopathological significance of insulin-like growth factor-I receptor (IGF1R), argininosuccinate synthetase 1 (ASS1), and pyrroline-5-carboxylate reductase 1 (PYCR1) in OSCC was analysed using tissue micriarray (TMA). Metabolic abnormalities were determined by untargeted metabolomics analysis. The DDP-resistance role of IGF1R, ASS1, and PYCR1 in OSCC was investigated in vitro and in vivo. Results: Generally, tumour cells exist in a hypoxic microenvironment. By genomic profiling, we determined that IGF1R, as a receptor tyrosine kinase (RTK), was upregulated in OSCC under low-oxygen conditions. Clinically, enhanced IGF1R expression was associated with higher tumour stages and a poorer prognosis in OSCC patients, and its inhibitor, linsitinib, showed synergistic effects with DDP therapy in vivo and in vitro. Since oxygen-deprivation frequently lead to metabolic reprogramming, we further learned via metabolomics analysis that abnormal IGF1R pathways promoted the expression of metabolic enzymes ASS1 and PYCR1 by the transcriptional activity of c-MYC. In detail, enhanced expression of ASS1 promotes arginine metabolism for biological anabolism, whereas PYCR1 activates proline metabolism for redox balance, which maintains the proliferation ability of OSCC cells during DDP treatment under hypoxic conditions. Conclusion: Enhanced expression of ASS1 and PYCR1 via IGF1R pathways rewired arginine and proline metabolism, promoting DDP resistance in OSCC under hypoxia. Linsitinib targeting IGF1R signaling may lead to promising combination therapy options for OSCC patients with DDP resistance.

The mechanism by which SIRT1 regulates autophagy and EMT in drug-resistant oesophageal cancer cells

Ferritinophagy Mediates Adaptive Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy

Autophagy determines osimertinib resistance through regulation of stem cell-like properties in EGFR-mutant lung cancer

Protective Autophagy Decreases Osimertinib Cytotoxicity Through Regulation of Stem Cell-Like Properties in Lung Cancer

Cellular Molecular and Proteomic Profiling Deciphers the SIRT1 Controlled Cell Death Pathways in Esophageal Adenocarcinoma Cells

EMT and Cancer Cell Stemness Associated With Chemotherapeutic Resistance in Esophageal Cancer

SIRT1 is a Regulator of Autophagy: Implications in Gastric Cancer Progression and Treatment

Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer

Sestrin2-Mediated Autophagy Contributes to Drug Resistance via Endoplasmic Reticulum Stress in Human Osteosarcoma

SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer

SIRT1 Inhibits Chemoresistance and Cancer Stemness of Gastric Cancer by Initiating an AMPK/FOXO3 Positive Feedback Loop

Targeting Non-Canonical Autophagy Overcomes Erlotinib Resistance in Tongue Cancer.

Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors

SIRT1 Promotes Chemoradiotherapy Resistance in Esophageal Squamous Cell Carcinoma

Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma

Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia

Disruption of the EGFR-SQSTM1 Interaction by a Stapled Peptide Suppresses Lung Cancer Via Activating Autophagy and Inhibiting EGFR Signaling.

Autophagy Enhanced the Radioresistance of Non-Small Cell Lung Cancer by Regulating ROS Level under Hypoxia Condition

Role of sirtuin 1 (SIRT1) in regulation of autophagy and nuclear factor-kappa Beta (NF-ĸβ) pathways in sorafenib-resistant hepatocellular carcinoma (HCC)